login
  Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

The future of remote monitoring


Thursday, 15 Dec 2011 11:22
Stefan Sack
Stefan Sack


Stefan Sack, chair and director, Department of Cardiology, Pneumology and Intensive Care Medicine, Academic General Hospital Munich, Germany, speaks to Cardiac Rhythm News about what current data for remote monitoring shows and what studies on remote monitoring are currently investigating.


On the whole, what do we know about remote monitoring of cardiac devices compared with standard in-hospital follow-up?

 

There is fundamental evidence that remote monitoring can reduce follow-up burden and costs and that it can improve patient outcomes. For example, the REFORM study (Hindricks G et al, Dtsch Ärztebl 2008: 105:156-9) and the TRUST study (Varma et al, Circulation 2010; 122:325-32) demonstrated a decline in patient adherence with standard in-hospital follow-up and a reduction in costs.

 

Both the ECOST and EVATEL studies, which were presented at the European Society of Cardiology 2011 annual meeting, showed that remote monitoring reduced the number of inappropriate shocks. What are the reasons behind this and what are the implications of this result?

 

In the ECOST trial, my understanding is that the early detection capabilities of remote monitoring (Biotronik Home Monitoring) allowed early identification of changes in the clinical condition such that an intervention, like a modification of medication, could occur before the patient’s condition worsens to the point that a shock occurs. The implications for this are increased battery longevity of the implant, which is an economic benefit because the patient gets more treatment days out of one device. Furthermore, there is an improvement of care due to reducing inappropriate and potentially painful shock delivery.

 

We are still waiting for data for the cost-effectiveness of remote monitoring. Do you think remote monitoring will be shown to be cost effective and how important is it to the future of remote monitoring that it is found to be cost-effective?

 

Convincing health economic data, although not necessarily cost-effectiveness data in a methodological sense, will remain crucial to allow payers to assess whether remote monitoring provides value for money compared with alternative investments. Economic data are available that show remote monitoring to have potential to be either cost neutral or cost-effective, depending on the healthcare system that uses it.

 

In addition, for hospitals, economic and quality of care considerations become more and more important as hospitals face an increasing demand for their services (due to an ageing population and an increasing adoption of device therapy), significant cost pressure (eg. in the form of fixed case payments in some diagnosis-related group systems), and quality demands from payers (eg. the “payment by results” initiative in the UK, although devices are not part of this initiative).

 

Randomised controlled trials and observational evidence have shown that by using remote monitoring, hospitals can tailor their service provision to patients that have an actual medical need for in-hospital follow-up visits. Considering that between 71% and 93% of all calendar-based in-hospital follow-up visits do not need further action, there is an enormous potential for streamlining hospital services and increasing efficiency at no compromise to patient safety.

 

On the whole, do you think that patients/doctors trust remote monitoring? (ie, if using remote monitoring, do they also use standard in-hospital follow-up just in case?) and how can doctors/patients be encouraged to trust remote monitoring?

 

Remote monitoring is a tool that can be seen as an extension in-patient care from the physician’s point of view. Outside of office hours, the patient is under surveillance. Clinical events are monitored at 24 hours a day, seven days a week; the doctor can be informed right away of an event or at scheduled intervals. The patient’s primary care physician must be sent the information provided by the device and this information must be analysed by the referring hospital or cardiologist. Scepticism about the benefits of remote monitoring is high but once the patient has seen the benefits of remote monitoring, I do not think they will miss an in-hospital follow-up.

 

Shaunmugam et al (Europace 2011; Epub) recently showed that device-detected atrial high-rate events were associated with an increased incidence of thromboembolic events. What are the implications of this?

 

Atrial fibrillation is silent and undetected in 30% of cases. Almost one third of episodes can be detected by a remote monitoring device. This has implications for using device therapy with anticoagulants and/or antiarrhythmic therapy.

 

Are there any data or any current studies that show whether the detection of atrial high-rate events with remote monitoring can reduce the risk of stroke or other adverse outcomes?

 

Currently there are a number of studies in the pipeline on this issue, such as EchoCRt and Home PAT.

There are reports given that detection of atrial fibrillation and subsequent therapeutic consequences might improve mortality and morbidity. The COMPAS study (European Heart Journal 2011 Epub) demonstrated that remote monitoring (Home Monitoring, Biotronik) allows earlier intervention for pacemaker patients and showed a 66% reduction in hospitalisation for atrial arrhythmia and related strokes. Another study, IMPACT, is comparing anticoagulation by atrial tachycardia episodes detected by remote monitoring with conventional physician-directed anticoagulation criteria. The composite endpoint is stroke, systemic embolism, and major bleeding.

 

What are the advantages of remote monitoring for the patient’s quality of life? Are there any disadvantages?

 

Based on the available evidence so far, the quality of life in patients who are monitored remotely is maintained. This has been confirmed in several studies, using different tools. The hypothesis that patients who receive remote monitoring would be concerned that they are not being properly cared for has not been realised.

By using remote monitoring technology, patients can be relieved from having to attend unnecessary in clinic visits and spared the burden of travelling. Unfortunately, quite often, such real benefits for patients are left out when payers make decisions about funding.

 

Do you think there will ever be a point where all cardiac devices are monitored remotely?

 

The adoption of remote monitoring technology of devices is hampered by the widespread lack of reimbursement for either the transmitter device or the remote physician service or for the ongoing data transmission costs, or all three of them.




Add New Comment

Related Items


Most popular


Friday, 18 Jul 2014
Even in moderation, consumption of wine and hard liquor may be a risk factor for atrial fibrillation, according to new research recently published in the Journal of the American College of Cardiology.... Moderate alcohol use associated with increased risk for atrial fibrillation

Physicians implant world's first ProMRI Quadripolar CRT-D system to treat heart failure
Tuesday, 15 Jul 2014
With Sentus quadripolar leads and the Inventra series, Biotronik offers the only devices for patients with heart failure worldwide that are approved for MRI use. Physicians implant world's first ProMRI Quadripolar CRT-D system to treat heart failure

FDA approves Attain Performa quadripolar lead and Viva Quad CRT-Ds
Thursday, 07 Aug 2014
Medtronic has received US Food and Drug Administration (FDA) approval for the Attain Performa Model 4298 quadripolar lead, and the Viva Quad XT and Viva Quad S cardiac resynchronisation therapy ... FDA approves Attain Performa quadripolar lead and Viva Quad CRT-Ds

Features


A biological pacemaker is on its way
Wednesday, 13 Aug 2014
After over 10 years of research, scientists in the United States have demonstrated—for the first time—the feasibility of a somatic cell reprogramming strategy for creating a biological pacemaker in a ... A biological pacemaker is on its way

Sports for young patients with implantable cardioverter defibrillators: Refining the risk
Wednesday, 13 Aug 2014
Elizabeth Saarel (University of Utah, Salt Lake City, USA) argues that, based on prospective registry data, young patients with implantable cardioverter defibrillators can participate safely in ... Sports for young patients with implantable cardioverter defibrillators: Refining the risk

Profiles


Nick Linker
Monday, 14 Jul 2014
Nick Linker is president-elect of the British Heart Rhythm Society (BHRS) and programme director of ... Nick Linker

Richard Fogel
Thursday, 08 May 2014
Richard Fogel, president-elect of the Heart Rhythm Society and chief executive officer at St V... Richard Fogel

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions